Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

被引:68
作者
Creutzig, Ursula
Diekamp, Sylke
Zimmermann, Martin
Reinhardt, Dirk
机构
[1] Univ Munster, Childrens Hosp, Dept Pediat Hematol & Oncol, D-4400 Munster, Germany
[2] Sch Med, Dept Pediat Hematol & Oncol, Hannover, Germany
关键词
AML; children; early anthracycline cardiotoxicity; late anthracycline cardiotoxicity;
D O I
10.1002/pbc.21105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Anthracyclines are effective antineoplastic drugs in acute myelogenous leukemia (AML). However, their use is limited by cardiomyopathy, which occurs in children already at cumulative doses of 300 mg/m(2) (given as daunorubicin equivalent). Procedure. To evaluate anthracycline-associated cardiomyopathy in pediatric AML-patients, the incidence of early and late (> 1 year after intensive AML chemotherapy) clinical and subclinical cardiotoxicity was analyzed out of a total of 1,207 patients < 18 years treated between 1993 and 2003 in trials AML-BFM93/98: 1,010 protocol patients with de novo AML, 121 with Down syndrome (DS)-AML, and 76 with secondary AML. The Cumulative dose of anthracyclines was generally risk-adapted: 300-450 mg/m(2) using 1-4-hr infusions of anthracyclines with the assumed lowest cardiotoxic potential. Eight hundred eighty-five patients (73%) were eligible for the analysis of early and 547 (45%) of late cardiotoxicity (1,399 follow-up data). Results. Thirty-eight patients (4.3%), including 3 DS-AML and 1 secondary AML, suffered from early cardiomyopathy. After 5 years, four patients showed temporarily or persistently a reduced shortening fraction, which led to death in one DS-AML patient. Including these 4 patients, late cardiomyopathy was seen in 16 patients (cumulative incidence after 11 years: 5% +/- 1%). Nine patients (2.5 +/- 1%) showed clinical symptoms, five of them had persistent abnormal shortening fraction. Late subclinical cardiomyopathy occurred temporarily in seven patients. Late clinical cardiomyopathy mainly affected patients with a second anthracycline therapy (secondary malignancy) and those with early cardiotoxicity. Conclusion. In spite of a highly intensive and effective treatment, the frequency of anthracycline-associated cardiomyopathy was low in the AML-BFM studies. Pediatr Blood Cancer 2007;48:651-662. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:651 / 662
页数:12
相关论文
共 51 条
[21]   Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia - Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity inpatients treated for acute leukaemia at the University Hospital of Zurich, Switzerland, between 1990 and 1996 [J].
Dazzi, H ;
Kaufmann, K ;
Follath, F .
ANNALS OF ONCOLOGY, 2001, 12 (07) :963-966
[22]   Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors [J].
DeWolf, D ;
Suys, B ;
Maurus, R ;
Benoit, Y ;
Verhaaren, H ;
Matthijs, D ;
Otten, J .
PEDIATRIC RESEARCH, 1996, 39 (03) :504-512
[23]  
Elbl Lubomir, 2003, Kardiol Pol, V58, P190
[24]   Editorial - Exercise echocardiography reflects cumulative anthracycline exposure during childhood [J].
Ewer, MS .
PEDIATRIC BLOOD & CANCER, 2004, 42 (07) :554-555
[25]  
Forssen Eric A., 1994, Journal of Liposome Research, V4, P481, DOI 10.3109/08982109409037058
[26]   CARDIOMYOPATHY AFTER TREATMENT FOR OSTEOSARCOMA - A CONTRIBUTION TO CARDIOTOXICITY OF ADRIAMYCIN [J].
GEIDEL, S ;
GARN, M ;
GRAVINGHOFF, L ;
HAUSDORF, G ;
MORF, G ;
BIELACK, S ;
KNOP, J ;
WINKLER, K .
KLINISCHE PADIATRIE, 1991, 203 (04) :257-261
[27]   Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines [J].
Germanakis, I ;
Kalmanti, M ;
Parthenakis, F ;
Nikitovic, D ;
Stiakaki, E ;
Patrianakos, A ;
Vardas, PE .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 108 (02) :212-215
[28]   Anthracycline-induced cardiotoxicity in children and young adults [J].
Giantris, A ;
Abdurrahman, L ;
Hinkle, A ;
Asselin, B ;
Lipshultz, SE .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1998, 27 (01) :53-68
[29]   Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma [J].
Gill, PS ;
Wernz, J ;
Scadden, DT ;
Cohen, P ;
Mukwaya, GM ;
vonRoenn, JH ;
Jacobs, M ;
Kempin, S ;
Silverberg, I ;
Gonzales, G ;
Rarick, MU ;
Myers, AM ;
Shepherd, F ;
Sawka, C ;
Pike, MC ;
Ross, ME .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2353-2364
[30]  
Grenier MA, 1998, SEMIN ONCOL, V25, P72